SUTRO BIOPHARMA, INC. Restructuring Charges
SUTRO BIOPHARMA, INC. (STRO) reported Restructuring Charges of $0 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-05-14
- SUTRO BIOPHARMA, INC. restructuring charges for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- SUTRO BIOPHARMA, INC. restructuring charges for the quarter ending 2025-12-31 was $1.09M.
- SUTRO BIOPHARMA, INC. restructuring charges for the quarter ending 2025-09-30 was $2.63M.
- SUTRO BIOPHARMA, INC. restructuring charges for the quarter ending 2025-06-30 was $1.38M.
- SUTRO BIOPHARMA, INC. restructuring charges for fiscal 2025 was $12.80M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | $1.09M derived: sum of 2 quarters · filed 2026-05-14 | $3.72M derived: sum of 3 quarters · filed 2026-05-14 | $5.09M derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.72M derived: sum of 2 quarters · filed 2026-03-23 | $5.09M derived: sum of 3 quarters · filed 2026-03-23 | $12.80M 10-K · filed 2026-03-23 |
| 2025-09-30 | $2.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.01M derived: sum of 2 quarters · filed 2025-11-06 | $11.71M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $9.08M 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | $7.70M 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |